Aerovate Therapeutics Inc (AVTE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aerovate Therapeutics Inc (AVTE) has a cash flow conversion efficiency ratio of -0.032x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.38 Million) by net assets ($75.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Aerovate Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
Aerovate Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Aerovate Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aerovate Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aerovate Therapeutics Inc ranked by their cash flow conversion efficiency. See Aerovate Therapeutics Inc (AVTE) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PolyPid
NASDAQ:PYPD
|
-2.876x |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
0.004x |
|
Super Dragon Technology Co Ltd
TW:9955
|
0.036x |
|
Hyundai Livart Furniture Co Ltd
KO:079430
|
-0.004x |
|
Daemyung Sonoseason Co.Ltd
KQ:007720
|
-0.048x |
|
Lifevantage Corporation
NASDAQ:LFVN
|
0.142x |
|
Asetek A/S
F:A31
|
0.018x |
|
MAIA Biotechnology Inc.
NYSE MKT:MAIA
|
-0.191x |
Annual Cash Flow Conversion Efficiency for Aerovate Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Aerovate Therapeutics Inc from 2019 to 2024. View AVTE stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $76.43 Million | $-71.20 Million | -0.931x | -79.57% |
| 2023-12-31 | $109.46 Million | $-56.78 Million | -0.519x | -68.05% |
| 2022-12-31 | $126.74 Million | $-39.12 Million | -0.309x | -94.24% |
| 2021-12-31 | $172.42 Million | $-27.40 Million | -0.159x | -126.98% |
| 2020-12-31 | $-13.34 Million | $-7.86 Million | 0.589x | -22.85% |
| 2019-12-31 | $-3.64 Million | $-2.78 Million | 0.763x | -- |
About Aerovate Therapeutics Inc
Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts.